|
2024
|
P/S
|
Chemical, biochemical, biological, and biotechnological
preparations, especially antibodies, and... |
|
|
Invention
|
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor ... |
|
|
Invention
|
Antibodies binding to fibroblast activation protein alpha and death receptor 4. The present inven... |
|
|
Invention
|
Methods of treating cd20 expressing b-cell cancers.
The present invention relates to improved me... |
|
|
Invention
|
Highly purified epcoritamab compositions.
The present disclosure provides highly purified epcori... |
|
|
Invention
|
Highly purified epcoritamab compositions. The present disclosure provides highly purified epcorit... |
|
|
Invention
|
Methods of treating cd20 expressing b-cell cancers. The present invention relates to improved met... |
|
|
Invention
|
Antibodies capable of binding to ox40, variants thereof and uses thereof.
The present invention ... |
|
|
Invention
|
Antibodies capable of binding to ox40, variants thereof and uses thereof. The present invention r... |
|
|
Invention
|
Methods of treating lymphoma with bispecific antibodies against cd3 and cd20.
The present invent... |
|
|
Invention
|
Methods of treating lymphoma with bispecific antibodies against cd3 and cd20. The present inventi... |
|
|
Invention
|
Multispecific binding agents against pd-l1 and cd137 for treating cancer. The present invention r... |
|
|
Invention
|
Pharmaceutical compositions comprising antibodies binding to cd30 and cd3. The present invention ... |
|
|
Invention
|
Antibodies.
The present invention relates to antibodies binding to 5T4, including bispecific ant... |
|
|
Invention
|
Bispecific antibodies against her2.
Bispecific antibodies which comprise antigen-binding regions... |
|
|
P/S
|
Medical and pharmacological research services; scientific research in the nature of conducting cl... |
|
|
P/S
|
Medical and pharmacological research services; clinical
trials; providing medical and scientific... |
|
|
Invention
|
Variants of cd38 antibody and uses thereof.
Antibody variants comprising one or more mutations i... |
|
|
P/S
|
Pharmaceuticals for the prevention and treatment of disorders of the nervous system, the immune s... |
|
|
P/S
|
Pharmaceuticals. Medical and pharmacological research services; clinical
trials; providing medic... |
|
2023
|
Invention
|
Antibodies against pd-l1.
The present invention relates to novel antibodies and their use in med... |
|
|
Invention
|
Human antibody drug conjugates against tissue factor.
Antibody drug conjugates against tissue fa... |
|
|
Invention
|
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemoth... |
|
|
Invention
|
Heterodimeric antibody fc-containing proteins and methods for production thereof.
Novel heterodi... |
|
|
Invention
|
Bispecific antibodies against cd3 and cd20 for treating richter's syndrome. Provided are methods ... |
|
|
Invention
|
Cd38 antibodies and uses thereof. The present invention relates to anti-CD38 antibodies comprisin... |
|
|
Invention
|
Combination treatment of cd38-expressing tumors.
The invention relates to novel method for the t... |
|
|
Invention
|
Agonistic tnf receptor binding agents.
The present invention relates to binding agents binding t... |
|
|
Invention
|
Antibodies binding to cd30 and cd3.
The invention relates to multispecific antibodies binding to... |
|
|
P/S
|
Chemical, biochemical, biological, and biotechnological preparations, namely, antibodies and bi- ... |
|
|
Invention
|
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis bindin... |
|
|
Invention
|
Antibodies against cd38 for treatment of multiple myeloma.
Isolated human monoclonal antibodies ... |
|
|
Invention
|
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
The invent... |
|
|
P/S
|
Medical and pharmacological research services; clinical trials; providing medical and scientific ... |
|
|
P/S
|
Pharmaceuticals. Medical and pharmacological research services; Clinical trials; Providing medica... |
|
|
Invention
|
Modified immunoglobulin with affinity for fcgammariib and method of use thereof.
Immunotherapeut... |
|
|
P/S
|
Provision of consumer information in the field of patient reimbursement and medical benefit suppo... |
|
|
Invention
|
Binding agents capable of binding to cd27 in combination therapy. The present invention provides ... |
|
|
Invention
|
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine. The ... |
|
|
P/S
|
Chemical, biochemical, biological, and biotechnological preparations, especially antibodies, and ... |
|
|
Invention
|
Antibodies binding axl.
The present invention relates to anti-AXL antibodies, immunoconjugates, ... |
|
|
P/S
|
pharmaceutical preparations and substances for the treatment of oncological related diseases and ... |
|
|
Invention
|
Humanized or chimeric cd3 antibodies.
The present invention relates to humanized or chimeric ant... |
|
|
Invention
|
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell... |
|
|
P/S
|
Biological preparations for use in industry and science for in vitro and in vivo scientific and i... |
|
2022
|
Invention
|
Antibody-drug conjugate lyophilised formulation.
Disclosed herein are surfactant free lyophilize... |
|
|
Invention
|
Human antibodies against tissue factor and methods of use thereof.
Isolated human monoclonal ant... |
|
|
Invention
|
Monoclonal antibodies against c-met.
Isolated monoclonal antibodies which bind to human c-Met, t... |
|
|
Invention
|
Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for... |
|
|
Invention
|
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer.
The prese... |
|
|
Invention
|
Combination dosage regime of cd137 and pd-l1 binding agents.
The present invention relates to a ... |
|
|
Invention
|
Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3.
The presen... |
|
|
Invention
|
Non-activating antibody variants.
Described herein are proteins comprising an Fc region or the l... |
|
|
Invention
|
Multispecific binding agents against cd40 and cd137 in therapy.
The present disclosure relates g... |
|
2021
|
Invention
|
Antibody and taxane combination therapy.
The present invention provides combination therapy to r... |
|
|
Invention
|
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3.
The pre... |
|
|
P/S
|
Providing medical and scientific research information in the field of pharmaceuticals and clinica... |
|
2020
|
P/S
|
Pharmaceutical preparations for use in humans, namely,
chemotherapeutics and biopharmaceuticals;... |
|
2019
|
Invention
|
Trogocytosis-mediated therapy using cd38 antibodies.
Antibody variants for therapeutic use invol... |
|
2018
|
P/S
|
Pharmaceutical preparations for use in humans, namely, chemotherapeutics and biopharmaceuticals; ... |
|
2013
|
P/S
|
[ Chemical, ] biochemical, biological and biotechnological preparations, especially antibodies, a... |
|
|
P/S
|
Chemicals used in industry, science and photography,
including biochemicals, especially, monoclo... |
|
2012
|
P/S
|
Chemicals used in industry, science and photography, including biochemicals, especially, monoclon... |
|
2010
|
P/S
|
Chemicals used in industry, science and photography,
including biochemicals, especially monoclon... |
|
|
P/S
|
Biochemicals, namely, monoclonal antibodies for in vivo or in vitro scientific research and devel... |
|
|
P/S
|
Chemicals used in industry, science and photography, including biochemicals, especially monoclona... |
|
2007
|
P/S
|
Biochemical, namely, monoclonal antibodies for in vivo or in vitro scientific research and in viv... |
|
|
P/S
|
Pharmaceutical preparations and substances. |
|
2006
|
P/S
|
Medical scientific research, namely, biological scientific research into human monoclonal antibod... |
|
|
P/S
|
Biochemicals, namely monoclonal antibodies for in vivo or in vitro scientific research and develo... |
